Transporter-mediated drug-drug interactions with oral antidiabetic drugs

Pharmaceutics

Volumn 3, Issue 4, 2011, Pages 680-705

  Klatt, Sabine ^a   Fromm, Martin F ^a   König, Jörg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ABC (ATP binding cassette) transporter; Drug drug interaction; Multidrug and toxin extrusion protein (MATE); Oral antidiabetic drug; Organic anion transporting polypeptide (OATP); Organic cation transporter (OCT); P glycoprotein

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ATORVASTATIN; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; CARRIER PROTEIN; CLARITHROMYCIN; DIPEPTIDYL PEPTIDASE IV; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; MULTIDRUG RESISTANCE PROTEIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL CULTURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME INHIBITION; FLUID RETENTION; FOOD DRUG INTERACTION; FRACTURE; GLUCONEOGENESIS; GRAPEFRUIT JUICE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INHIBITION KINETICS; INSULIN RELEASE; LACTIC ACIDOSIS; LIVER DISEASE; NAUSEA; PANCREAS ISLET BETA CELL; PROTEIN FAMILY; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 84255204816     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3040680     Document Type: Review

References (129)

1. Hediger, M.A.; Romero, M.F.; Peng, J.B.; Rolfs, A.; Takanaga, H.; Bruford, E.A. The ABCs of Solute Carriers: Physiological, Pathological and Therapeutic Implications of Human Membrane Transport Proteins. Pflugers Arch. 2004, 447, 465-468
2. SLC. Available online: www.bioparadigms.org/SLC (accessed on 11 July 2011)
3. Hagenbuch, B.; Meier, P.J. Organic Anion Transporting Polypeptides of the OATP/SLC21 Family: Phylogenetic Classification as OATP/ SLCO Superfamily, New Nomenclature and Molecular/Functional Properties. Pflugers Arch. 2004, 447, 653-665
4. König, J. Uptake Transporters of the Human OATP Family: Molecular Characteristics, Substrates, Their Role in Drug-Drug Interactions, and Functional Consequences of Polymorphisms. In Handbook of Experimental Pharmacology; Springer Verlag: Berlin, Germany, 2011; pp. 1-28
5. Seithel, A.; Glaeser, H.; Fromm, M.F.; König, J. The Functional Consequences of Genetic Variations in Transporter Genes Encoding Human Organic Anion-Transporting Polypeptide Family Members. Expert Opin. Drug Metab. Toxicol. 2008, 4, 51-64
6. Kindla, J.; Fromm, M.F.; König, J. In Vitro Evidence for the Role of OATP and OCT Uptake Transporters in Drug-Drug Interactions. Expert Opin. Drug Metab. Toxicol. 2009, 5, 489-500
7. Fahrmayr, C.; Fromm, M.F.; König, J. Hepatic OATP and OCT Uptake Transporters: Their Role for Drug-Drug Interactions and Pharmacogenetic Aspects. Drug Metab. Rev. 2010, 42, 380-401
8. Koepsell, H.; Endou, H. The SLC22 Drug Transporter Family. Pflugers Arch. 2004, 447, 666-676
9. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W.P.; Kirchgessner, T.G. A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2). Identification of a Liver- Specific Human Organic Anion Transporting Polypeptide and Identification of Rat and Human Hydroxymethylglutaryl-CoA Reductase Inhibitor Transporters. J. Biol. Chem. 1999, 274, 37161-37168
10. König, J.; Seithel, A.; Gradhand, U.; Fromm, M.F. Pharmacogenomics of Human OATP Transporters. Naunyn-Schmied. Arch. Pharmacol. 2006, 372, 432-443
11. König, J.; Cui, Y.; Nies, A.T.; Keppler, D. A Novel Human Organic Anion Transporting Polypeptide Localized to the Basolateral Hepatocyte Membrane. Am. J. Physiol. Gastrointest Liver Physiol. 2000, 278, G156-G164
12. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I. Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane. J. Pharmacol. Exp. Ther. 2003, 306, 703-708
13. Grube, M.; Köck, K.; Oswald, S.; Draber, K.; Meissner, K.; Eckel, L.; Bohm, M.; Felix, S.B.; Vogelgesang, S.; Jedlitschky, G.; Siegmund, W.; Warzok, R.; Kroemer, H.K. Organic Anion Transporting Polypeptide 2B1 Is a High-Affinity Transporter for Atorvastatin and Is Expressed in the Human Heart. Clin. Pharmacol. Ther. 2006, 80, 607-620
14. Koepsell, H.; Lips, K.; Volk, C. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications. Pharm. Res. 2007, 24, 1227-1251
15. Nies, A.T.; Koepsell, H.; Winter, S.; Burk, O.; Klein, K.; Kerb, R.; Zanger, U.M.; Keppler, D.; Schwab, M.; Schaeffeler, E. Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver. Hepatology 2009, 50, 1227-1240
16. Gorboulev, V.; Ulzheimer, J.C.; Akhoundova, A.; Ulzheimer-Teuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.; Busch, A.E.; Koepsell, H. Cloning and Characterization of Two Human Polyspecific Organic Cation Transporters. DNA Cell Biol. 1997, 16, 871-881
17. Hagenbuch, B.; Meier, P.J. Molecular Cloning, Chromosomal Localization, and Functional Characterization of a Human Liver Na+/Bile Acid Cotransporter. J. Clin. Invest. 1994, 93, 1326-1331
18. Jonker, J.W.; Schinkel, A.H. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 2004, 308, 2-9
19. Niessen, J.; Jedlitschky, G.; Grube, M.; Bien, S.; Schwertz, H.; Ohtsuki, S.; Kawakami, H.; Kamiie, J.; Oswald, S.; Starke, K.; Strobel, U.; Siegmund, W.; Rosskopf, D.; Greinacher, A.; Terasaki, T.; Kroemer, H.K. Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metab. Dispos. 2009, 37, 1129-1137
20. Kameyama, Y.; Yamashita, K.; Kobayashi, K.; Hosokawa, M.; Chiba, K. Functional Characterization of SLCO1B1 (OATP-C) Variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by Using Transient Expression Systems of HeLa and HEK293 Cells Pharmacogenet. Genomics 2005, 15, 513-522
21. Schwarz, U.I.; Meyerzu Schwabedissen, H.E.; Tirona, R.G.; Suzuki, A.; Leake, B.F.; Mokrab, Y.; Mizuguchi, K.; Ho, R.H.; Kim, R.B. Identification of Novel Functional Organic Anion- Transporting Polypeptide 1B3 Polymorphisms and Assessment of Substrate Specificity Pharmacogenet. Genomics 2011, 21, 103-114
22. Tamai, I.; Nezu, J.; Uchino, H.; Sai, Y.; Oku, A.; Shimane, M.; Tsuji, A. Molecular Identification and Characterization of Novel Members of the Human Organic Anion Transporter (OATP) Family. Biochem. Biophys. Res. Commun. 2000, 273, 251-260
23. Koepsell, H.; Schmitt, B.M.; Gorboulev, V. Organic Cation Transporters. Rev. Physiol. Biochem Pharmacol. 2003, 150, 36-90
24. Cha, S.H.; Sekine, T.; Fukushima, J.I.; Kanai, Y.; Kobayashi, Y.; Goya, T.; Endou, H Identification and Characterization of Human Organic Anion Transporter 3 Expressing Predominantly in the Kidney. Mol. Pharmacol. 2001, 59, 1277-1286
25. Cropp, C.D.; Komori, T.; Shima, J.E.; Urban, T.J.; Yee, S.W.; More, S.S.; Giacomini, K.M Organic Anion Transporter 2 (SLC22A7) Is a Facilitative Transporter of cGMP. Mol Pharmacol. 2008, 73, 1151-1158
26. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstadt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin Nephrotoxicity Is Critically Mediated Via the Human Organic Cation Transporter 2. Am. J. Pathol. 2005, 167, 1477-1484
27. Yonezawa, A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K. Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1- 3 and Multidrug and Toxin Extrusion Family). J. Pharmacol. Exp. Ther. 2006, 319, 879-886
28. Umehara, K.I.; Iwatsubo, T.; Noguchi, K.; Kamimura, H. Comparison of the Kinetic Characteristics of Inhibitory Effects Exerted by Biguanides and H2-Blockers on Human and Rat Organic Cation Transporter-Mediated Transport: Insight into the Development of Drug Candidates. Xenobiotica 2007, 37, 618-634
29. Ho, R.H.; Tirona, R.G.; Leake, B.F.; Glaeser, H.; Lee, W.; Lemke, C.J.; Wang, Y.; Kim, R.B Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology 2006, 130, 1793-1806
30. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A Family of Drug Transporters: The Multidrug Resistance-Associated Proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302
31. Deeley, R.G.; Westlake, C.; Cole, S.P. Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol. Rev. 2006, 86, 849-899
32. Keppler, D.; Kamisako, T.; Leier, I.; Cui, Y.; Nies, A.T.; Tsujii, H.; König, J. Localization, Substrate Specificity, and Drug Resistance Conferred by Conjugate Export Pumps of the MRP Family. Adv. Enzyme Regul. 2000, 40, 339-349
33. Dean, M.; Rzhetsky, A.; Allikmets, R. The Human ATP-Binding Cassette (ABC) Transporter Superfamily. Genome Res. 2001, 11, 1156-1166
34. ABC1 (subfamily A). Availabe online: www.nutrigene.4t.com/humanABC.Htm. (accessed on 11 July 2011)
35. Fromm, M.F. Importance of P-Glycoprotein for Drug Disposition in Humans. Eur. J. Clin. Invest 2003, 33, 6-9
36. Cascorbi, I. P-Glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations. In Handbook of Experimental Pharmacology; Springer Verlag: Berlin, Germany, 2011; pp. 261-283
37. Maliepaard, M.; Scheffer, G.L.; Faneyte, I.F.; van Gastelen, M.A.; Pijnenborg, A.C.; Schinkel, A.H.; van De Vijver, M.J.; Scheper, R.J.; Schellens, J.H. Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues Cancer Res. 2001, 61, 3458-3464
38. Huls, M.; Brown, C.D.; Windass, A.S.; Sayer, R.; van den Heuvel, J.J.; Heemskerk, S.; Russel, F.G.; Masereeuw, R. The Breast Cancer Resistance Protein Transporter ABCG2 Is Expressed in the Human Kidney Proximal Tubule Apical Membrane. Kidney Int. 2008, 73, 220-225
39. Stieger, B.; Meier, Y.; Meier, P.J. The Bile Salt Export Pump. Pflugers Arch. 2007, 453, 611-620
40. Hoffmann, U.; Kroemer, H.K. The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance. Drug Metab. Rev. 2004, 36, 669-701
41. Kivistö, K.T.; Niemi, M.; Fromm, M.F. Functional Interaction of Intestinal CYP3A4 and P-Glycoprotein. Fundam. Clin. Pharmacol. 2004, 18, 621-626
42. Fromm, M.F. P-Glycoprotein: A Defense Mechanism Limiting Oral Bioavailability and CNS Accumulation of Drugs. Int. J. Clin. Pharmacol. Ther. 2000, 38, 69-74
43. Schwabedissen, H.E.; Kroemer, H.K. In Vitro and in Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2). In Handbook of Experimental Pharmacology; Springer Verlag: Berlin, Germany, 2011; pp. 325-371
44. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A Human Transporter Protein That Mediates the Final Excretion Step for Toxic Organic Cations. Proc Natl. Acad. Sci. USA 2005, 102, 17923-17928
45. Masuda, S.; Terada, T.; Yonezawa, A.; Tanihara, Y.; Kishimoto, K.; Katsura, T.; Ogawa, O.; Inui, K. Identification and Functional Characterization of a New Human Kidney-Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2. J. Am. Soc Nephrol. 2006, 17, 2127-2135
46. Tanihara, Y.; Masuda, S.; Sato, T.; Katsura, T.; Ogawa, O.; Inui, K. Substrate Specificity of MATE1 and MATE2-K, Human Multidrug and Toxin Extrusions/H+-Organic Cation Antiporters. Biochem. Pharmacol. 2007, 74, 359-371
47. Hagenbuch, B.; Meier, P.J. The Superfamily of Organic Anion Transporting Polypeptides Biochim. Biophys. Acta 2003, 1609, 1-18
48. Tamai, I. Oral Drug Delivery Utilizing Intestinal OATP Transporters. Adv. Drug Deliv. Rev 2011, In Press
49. Niemi, M. The Cytochrome P4503A4 Inhibitor Clarithromycin Increases the Plasma Concentrations and Effects of Repaglinide. Clin. Pharmacol. Ther. 2001, 70, 58-65
50. Niemi, M.; Backman, J.T.; Neuvonen, M.; Neuvonen, P.J. Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics and Pharmacodynamics of Repaglinide: Potentially Hazardous Interaction between Gemfibrozil and Repaglinide. Diabetologia 2003, 46, 347-351
51. Kajosaari, L.; Niemi, M.; Backman, J.; Neuvonen, P. Telithromycin, but Not Montelukast, Increases the Plasma Concentrations and Effects of the Cytochrome P450 3A4 and 2C8 Substrate Repaglinide. Clin. Pharmacol. Ther. 2006, 79, 231-242
52. Kajosaari, L.; Niemi, M.; Neuvonen, M.; Laitila, J.; Neuvonen, P.; Backman, J. Cyclosporine Markedly Raises the Plasma Concentrations of Repaglinide. Clin. Pharmacol. Ther. 2005, 78, 388-399
53. Zhou, L.; Naraharisetti, S.B.; Liu, L.; Wang, H.; Lin, Y.S.; Isoherranen, N.; Unadkat, J.D.; Hebert, M.F.; Mao, Q. Contributions of Human Cytochrome P450 Enzymes to Glyburide Metabolism. Biopharm. Drug Dispos. 2010, 31, 228-242
54. Satoh, H. Citrus Juices Inhibit the Function of Human Organic Anion-Transporting Polypeptide OATP-B. Drug Metab. Dispos. 2005, 33, 518-523
55. Naritomi, Y.; Terashita, S.; Kagayama, A. Identification and Relative Contributions of Human Cytochrome P450 Isoforms Involved in the Metabolism of Glibenclamide and Lansoprazole: Evaluation of an Approach Based on the in Vitro Substrate Disappearance Rate. Xenobiotica 2004, 34, 415-427
56. Golstein, P.E.; Boom, A.; van Geffel, J.; Jacobs, P.; Masereel, B.; Beauwens, R P-Glycoprotein Inhibition by Glibenclamide and Related Compounds. Pflugers Arch. 1999, 437, 652-660
57. Gedeon, C.; Behravan, J.; Koren, G.; Piquette-Miller, M. Transport of Glyburide by Placental ABC Transporters: Implications in Fetal Drug Exposure. Placenta 2006, 27, 1096-1102
58. Kirchheiner, J.; Roots, I.; Goldammer, M.; Rosenkranz, B.; Brockmöller, J. Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance. Clin. Pharmacokinet. 2005, 44, 1209-1225
59. Niemi, M.; Neuvonen, P.J.; Kivistö, K.T. Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of Glimepiride. Clin. Pharmacol. Ther. 2001, 70, 439-445
60. Holstein, A.; Egberts, E.H. Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes. Exp. Clin. Endocrinol. Diabetes 2003, 111, 405-414
61. Proks, P.; Reimann, F.; Green, N.; Gribble, F.; Ashcroft, F. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002, 51, S368-S376
62. Bidstrup, T.B.; Bjornsdottir, I.; Sidelmann, U.G.; Thomsen, M.S.; Hansen, K.T. CYP2C8 and CYP3A4 Are the Principal Enzymes Involved in the Human in Vitro Biotransformation of the Insulin Secretagogue Repaglinide. Br. J. Clin. Pharmacol. 2003, 56, 305-314
63. Niemi, M.; Backman, J.T.; Kajosaari, L.I.; Leathart, J.B.; Neuvonen, M.; Daly, A.K.; Eichelbaum, M.; Kivistö, K.T.; Neuvonen, P.J. Polymorphic Organic Anion Transporting Polypeptide 1B1 Is a Major Determinant of Repaglinide Pharmacokinetics. Clin. Pharmacol Ther. 2005, 77, 468-478
64. Bachmakov, I.; Glaeser, H.; Fromm, M.F.; König, J. Interaction of Oral Antidiabetic Drugs with Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. Diabetes 2008, 57, 1463-1469
65. Niemi, M.; Backman, J.T.; Juntti-Patinen, L.; Neuvonen, M.; Neuvonen, P.J. Coadministration of Gemfibrozil and Itraconazole Has Only a Minor Effect on the Pharmacokinetics of the CYP2C9 and CYP3A4 Substrate Nateglinide. Br. J. Clin. Pharmacol. 2005, 60, 208-217
66. Kalliokoski, A.; Backman, J.T.; Neuvonen, P.J.; Niemi, M. Effects of the SLCO1B1*1B Haplotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide Pharmacogenet. Genomics 2008, 18, 937-942
67. Scheen, A.J. Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide. Clin. Pharmacokinet. 2007, 46, 93-108
68. Cox, P.J.; Ryan, D.A.; Hollis, F.J.; Harris, A.M.; Miller, A.K.; Vousden, M.; Cowley, H Absorption, Disposition, and Metabolism of Rosiglitazone, a Potent Thiazolidinedione Insulin Sensitizer, in Humans. Drug Metab. Dispos. 2000, 28, 772-780
69. Loi, C.M.; Young, M.; Randinitis, E.; Vassos, A.; Koup, J.R. Clinical Pharmacokinetics of Troglitazone. Clin. Pharmacokinet. 1999, 37, 91-104
70. Kirchheiner, J.; Thomas, S.; Bauer, S.; Tomalikscharte, D.; Hering, U.; Doroshyenko, O.; Jetter, A.; Stehle, S.; Tsahuridu, M.; Meineke, I. Pharmacokinetics and Pharmacodynamics of Rosiglitazone in Relation to CYP2C8 Genotype. Clin. Pharmacol. Ther. 2006, 80, 657-667
71. Solbach, T.F.; Paulus, B.; Weyand, M.; Eschenhagen, T.; Zolk, O.; Fromm, M.F. ATP-Binding Cassette Transporters in Human Heart Failure. Naunyn-Schmied. Arch. Pharmacol. 2008, 377, 231-243
72. Hemauer, S.J.; Patrikeeva, S.L.; Nanovskaya, T.N.; Hankins, G.D.V.; Ahmed, M.S. Role of Human Placental Apical Membrane Transporters in the Efflux of Glyburide, Rosiglitazone and Metformin. Am. J. Obstet. Gynecol. 2010, 202, 383.e1-e7
73. Tornio, A.; Niemi, M.; Neuvonen, P.J.; Backman, J.T. Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. Drug Metab. Dispos. 2008, 36, 73-80
74. Nozawa, T.; Sugiura, S.; Nakajima, M.; Goto, A.; Yokoi, T.; Nezu, J.; Tsuji, A.; Tamai, I Involvement of Organic Anion Transporting Polypeptides in the Transport of Troglitazone Sulfate: Implications for Understanding Troglitazone Hepatotoxicity. Drug Metab. Dispos. 2004, 32, 291-294
75. Gui, C.; Miao, Y.; Thompson, L.; Wahlgren, B.; Mock, M.; Stieger, B.; Hagenbuch, B. Effect of Pregnane X Receptor Ligands on Transport Mediated by Human OATP1B1 and OATP1B3. Eur J. Pharmacol. 2008, 584, 57-65
76. Weiss, J.; Sauer, A.; Herzog, M.; Böger, R.H.; Haefeli, W.E.; Benndorf, R.A. Interaction of Thiazolidinediones (Glitazones) with the ATP-Binding Cassette Transporters P-Glycoprotein and Breast Cancer Resistance Protein. Pharmacology 2009, 84, 264-270
77. Kis, E.; Ioja, E.; Nagy, T.; Szente, L.; Heredi-Szabo, K.; Krajcsi, P. Effect of Membrane Cholesterol on BSEP/Bsep Activity: Species Specificity Studies for Substrates and Inhibitors Drug Metab. Dispos. 2009, 37, 1878-1886
78. Martens, F.M.; Visseren, F.L.; Lemay, J.; de Koning, E.J.; Rabelink, T.J. Metabolic and Additional Vascular Effects of Thiazolidinediones. Drugs 2002, 62, 1463-1480
79. Giannini, S.; Serio, M.; Galli, A. Pleiotropic Effects of Thiazolidinediones: Taking a Look Beyond Antidiabetic Activity. J. Endocrinol. Invest. 2004, 27, 982-991
80. Kalaitzidis, R.G.; Sarafidis, P.A.; Bakris, G.L. Effects of Thiazolidinediones Beyond Glycaemic Control. Curr. Pharm. Des. 2009, 15, 529-536
81. Masubuchi, Y. Metabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review. Drug Metab. Pharmacokinet. 2006, 21, 347-356
82. Kimura, N.; Masuda, S.; Tanihara, Y.; Ueo, H.; Okuda, M.; Katsura, T.; Inui, K. Metformin Is a Superior Substrate for Renal Organic Cation Transporter OCT2 Rather Than Hepatic OCT1 Drug Metab. Pharmacokinet. 2005, 20, 379-386
83. Dunn, C.J.; Peters, D.H. Metformin. A Review of Its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus. Drugs 1995, 49, 721-749
84. Abbud, W.; Habinowski, S.; Zhang, J.Z.; Kendrew, J.; Elkairi, F.S.; Kemp, B.E.; Witters, L.A.; Ismail-Beigi, F. Stimulation of AMP-Activated Protein Kinase (AMPK) Is Associated with Enhancement of Glut1-Mediated Glucose Transport. Arch. Biochem. Biophys. 2000, 380, 347-352
85. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action. J. Clin. Invest. 2001, 108, 1167-1174
86. Kruse, J.A. Metformin-Associated Lactic Acidosis. J. Emerg. Med. 2001, 20, 267-272
87. Choi, M.K.; Jin, Q.R.; Ahn, S.H.; Bae, M.A.; Song, I.S. Sitagliptin Attenuates Metformin- Mediated AMPK Phosphorylation through Inhibition of Organic Cation Transporters Xenobiotica 2010, 40, 817-825
88. Chu, X.Y.; Bleasby, K.; Yabut, J.; Cai, X.; Chan, G.H.; Hafey, M.J.; Xu, S.; Bergman, A.J.; Braun, M.P.; Dean, D.C.; Evers, R. Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-Glycoprotein. J. Pharmacol. Exp. Ther. 2007, 321, 673-683
89. Scheen, A.J. Pharmacokinetics of Dipeptidylpeptidase-4 Inhibitors. Diabetes Obes. Metab. 2010, 12, 648-658
90. Kalliokoski, A.; Neuvonen, M.; Neuvonen, P.J.; Niemi, M. No Significant Effect of SLCO1B1 Polymorphism on the Pharmacokinetics of Rosiglitazone and Pioglitazone. Br. J. Clin Pharmacol. 2008, 65, 78-86
91. Kindla, J.; Müller, F.; Mieth, M.; Fromm, M.F.; König, J. Influence of Non-Steroidal Anti- Inflammatory Drugs on Organic Anion Transporting Polypeptide (OATP) 1B1- and OATP1B3- Mediated Drug Transport. Drug Metab. Dispos. 2011, 39, 1047-1053
92. Lilja, J.J.; Niemi, M.; Fredrikson, H.; Neuvonen, P.J. Effects of Clarithromycin and Grapefruit Juice on the Pharmacokinetics of Glibenclamide. Br. J. Clin. Pharmacol. 2007, 63, 732-740
93. Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P.J.; Backman, J.T The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h after the Dose: Evidence for Mechanism-Based Inhibition of CYP2C8 in Vivo. Clin. Pharmacol. Ther 2008, 84, 403-411
94. Kalliokoski, A.; Backman, J.T.; Kurkinen, K.J.; Neuvonen, P.J.; Niemi, M. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clin. Pharmacol. Ther. 2008, 84, 488-496
95. Bednarczyk, D. Fluorescence-Based Assays for the Assessment of Drug Interaction with the Human Transporters OATP1B1 and OATP1B3. Anal. Biochem. 2010, 405, 50-58
96. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo, A.; Fardel, O. The Sulphonylurea Glibenclamide Inhibits Multidrug Resistance Protein (MRP1) Activity in Human Lung Cancer Cells. Br. J. Pharmacol. 2001, 132, 778-784
97. Pollex, E.K.; Anger, G.; Hutson, J.; Koren, G.; Piquette-Miller, M. Breast Cancer Resistance Protein (BCRP)-Mediated Glyburide Transport: Effect of the C421A/Q141K BCRP Single- Nucleotide Polymorphism. Drug Metab. Dispos. 2010, 38, 740-744
98. Fuchikami, H. Effects of Herbal Extracts on the Function of Human Organic Anion-Transporting Polypeptide OATP-B. Drug Metab. Dispos. 2006, 34, 577-582
99. Pollex, E.; Lubetsky, A.; Koren, G. The Role of Placental Breast Cancer Resistance Protein in the Efflux of Glyburide across the Human Placenta. Placenta 2008, 29, 743-747
100. Gedeon, C.; Anger, G.; Piquette-Miller, M.; Koren, G. Breast Cancer Resistance Protein: Mediating the Trans-Placental Transfer of Glyburide across the Human Placenta. Placenta 2008, 29, 39-43
101. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Drug-Drug Interaction between Pitavastatin and Various Drugs Via OATP1B1. Drug Metab. Dispos. 2006, 34, 1229-1236
102. Zheng, H.X.; Huang, Y.; Frassetto, L.A.; Benet, L.Z. Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite. Clin. Pharmacol. Ther. 2008, 85, 78-85
103. Mita, S. Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB11)-Coexpressing LLC-PK1 Cells by Cholestasis- Inducing Drugs. Drug Metab. Dispos. 2006, 34, 1575-1581
104. Byrne, J.A.; Strautnieks, S.S.; Mieli-Vergani, G.; Higgins, C.F.; Linton, K.J.; Thompson, R.J The Human Bile Salt Export Pump: Characterization of Substrate Specificity and Identification of Inhibitors. Gastroenterology 2002, 123, 1649-1658
105. Meyer zu Schwabedissen, H.E.; Verstuyft, C.; Kroemer, H.K.; Becquemont, L.; Kim, R.B Human Multidrug and Toxin Extrusion 1 (MATE1/SLC47A1) Transporter: Functional Characterization, Interaction with OCT2 (SLC22A2), and Single Nucleotide Polymorphisms Am. J. Physiol. Renal. Physiol. 2010, 298, F997-F1005
106. Bachmakov, I.; Glaeser, H.; Endress, B.; Mörl, F.; König, J.; Fromm, M.F. Interaction of Beta- Blockers with the Renal Uptake Transporter OCT2. Diabetes Obes. Metab. 2009, 11, 1080-1083
107. Müller, F.; König, J.; Glaeser, H.; Schmidt, I.; Zolk, O.; Fromm, M.F.; Maas, R. Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine. Antimicrob Agents Chemother. 2011, 55, 3091-3098
108. Somogyi, A.; Stockley, C.; Keal, J.; Rolan, P.; Bochner, F. Reduction of Metformin Renal Tubular Secretion by Cimetidine in Man. Br. J.Clin. Pharmacol. 1987, 23, 545-551
109. Wang, Z.J.; Yin, O.Q.; Tomlinson, B.; Chow, M.S. OCT2 Polymorphisms and in-Vivo Renal Functional Consequence: Studies with Metformin and Cimetidine. Pharmacogenet. Genomics 2008, 18, 637-645
110. Zolk, O.; Solbach, T.F.; König, J.; Fromm, M.F. Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser. Drug Metab. Dispos. 2009, 37, 1312-1318
111. Tsuda, M.; Terada, T.; Ueba, M.; Sato, T.; Masuda, S.; Katsura, T.; Inui, K. Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. J. Pharmacol. Exp. Ther. 2009, 329, 185-191
112. Minematsu, T.; Giacomini, K.M. Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. Mol. Cancer Ther. 2011, 10, 531-539
113. Zolk, O.; Solbach, T.F.; König, J.; Fromm, M.F. Structural Determinants of Inhibitor Interaction with the Human Organic Cation Transporter OCT2 (SLC22A2). Naunyn-Schmied. Arch Pharmacol. 2008, 379, 337-348
114. Umehara, K.I.; Iwatsubo, T.; Noguchi, K.; Usui, T.; Kamimura, H. Effect of Cationic Drugs on the Transporting Activity of Human and Rat OCT/Oct 1-3 in Vitro and Implications for Drug-Drug Interactions. Xenobiotica 2008, 38, 1203-1218
115. Gui, C.; Obaidat, A.; Chaguturu, R.; Hagenbuch, B. Development of a Cell-Based High- Throughput Assay to Screen for Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3. Curr. Chem. Genomics 2010, 4, 1-8
116. Niemi, M.; Backman, J.T.; Neuvonen, M.; Neuvonen, P.J.; Kivistö, K.T. Rifampin Decreases the Plasma Concentrations and Effects of Repaglinide. Clin. Pharmacol. Ther. 2000, 68, 495-500
117. Gui, C.; Wahlgren, B.; Lushington, G.H.; Hagenbuch, B. Identification, Ki Determination and CoMFA Analysis of Nuclear Receptor Ligands as Competitive Inhibitors of OATP1B1-Mediated Estradiol-17beta-Glucuronide Transport. Pharmacol. Res. 2009, 60, 50-56
118. Marion, T.L.; Leslie, E.M.; Brouwer, K.L. Use of Sandwich-Cultured Hepatocytes to Evaluate Impaired Bile Acid Transport as a Mechanism of Drug-Induced Hepatotoxicity. Mol. Pharm 2007, 4, 911-918
119. Neuhoff, S.; Ungell, A.L.; Zamora, I.; Artursson, P. Ph-Dependent Bidirectional Transport of Weakly Basic Drugs across Caco-2 Monolayers: Implications for Drug-Drug Interactions Pharm. Res. 2003, 20, 1141-1148
120. Dresser, M.J.; Xiao, G.; Leabman, M.K.; Gray, A.T.; Giacomini, K.M. Interactions of NTetraalkylammonium Compounds and Biguanides with a Human Renal Organic Cation Transporter (hOCT2). Pharm. Res. 2002, 19, 1244-1247
121. Ahlin, G.; Karlsson, J.; Pedersen, J.M.; Gustavsson, L.; Larsson, R.; Matsson, P.; Norinder, U.; Bergstrom, C.A.; Artursson, P. Structural Requirements for Drug Inhibition of the Liver Specific Human Organic Cation Transport Protein 1. J. Med. Chem. 2008, 51, 5932-5942
122. Shu, Y.; Brown, C.; Castro, R.A.; Shi, R.J.; Lin, E.T.; Owen, R.P.; Sheardown, S.A.; Yue, L.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics. Clin. Pharmacol. Ther. 2008, 83, 273-280
123. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.; Castro, R.A.; Ianculescu, A.G.; Yue, L.; Lo, J.C.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of Genetic Variation in the Organic Cation Transporter 1 (OCT1) on Metformin Action. J. Clin. Invest. 2007, 117, 1422-1431
124. Zolk, O. Disposition of Metformin: Variability Due to Polymorphisms of Organic Cation Transporters. Ann. Med. 2011, in press.
125. Omote, H.; Hiasa, M.; Matsumoto, T.; Otsuka, M.; Moriyama, Y. The MATE Proteins as Fundamental Transporters of Metabolic and Xenobiotic Organic Cations. Trends Pharmacol. Sci 2006, 27, 587-593
126. Nies, A.T.; Koepsell, H.; Damme, K.; Schwab, M. Organic Cation Transporters (OCTs, MATEs), in Vitro and in Vivo Evidence for the Importance in Drug Therapy. In Handbook of Experimental Pharmacology; Springer Verlag: Berlin, Germany, 2011; pp. 105-167
127. Tsuda, M.; Terada, T.; Mizuno, T.; Katsura, T.; Shimakura, J.; Inui, K. Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin. Mol. Pharmacol. 2009, 75, 1280-1286
128. Sato, T.; Masuda, S.; Yonezawa, A.; Tanihara, Y.; Katsura, T.; Inui, K. Transcellular Transport of Organic Cations in Double-Transfected MDCK Cells Expressing Human Organic Cation Transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem. Pharmacol. 2008, 76, 894-903
129. König, J.; Zolk, O.; Singer, K.; Hoffmann, C.; Fromm, M.F. Double-Transfected MDCK Cells Expressing Human OCT1/MATE1 or OCT2/MATE1: Determinants of Uptake and Transcellular Translocation of Organic Cations. Br. J. Pharmacol. 2011, 163, 546-555